Despite the generally excellent prognosis of children and adolescents with Hodgkin's lymphoma (HL), approximately 15% of patients relapse. Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. Although patients with late relapse (412 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. Data on allogeneic HSCT in children with HL are scarce. Broader use has been hampered for a long time mainly by high non-relapse mortality, offsetting the advantage of a graft-vs-lymphoma effect. Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge.
Introduction
Hodgkin's lymphoma (HL) is one of the most curable malignant tumours in childhood and adolescence. With current polychemotherapy regimens combined with lowdose radiotherapy cure rates exceed 90%. [1] [2] [3] [4] As standardized treatment protocols show high efficacy, an increasing effort has been undertaken to reduce long-term side effects associated with treatment. Therefore, radiotherapy doses have been steadily decreased, splenectomy has been abandoned and the use of gonadotoxic substances, such as procarbazine, has been reduced while maintaining the good treatment results. 5, 6 Limited data have been published on paediatric patients with recurring HL. 7, 8 Recently, it has been shown that paediatric and adolescent patients with HL receiving ST-HD-86 salvage therapy had a favourable outcome. 9 Among 176 patients, 51 showed disease progression (during or o3 months after completion of therapy), 57 had an early relapse (3-12 months after therapy) and 68 presented with the first late relapse (412 months). Treatment was based on two regimens, ifosfamide, etoposide and prednisone and adriamycin, bleomycin, vinblastine and dacarbazine. Involved-field irradiation was dependent on the fields and doses applied during first-line therapy. With a median follow-up of 5 years, probabilities for overall survival (OS) and disease-free survival (DFS) at 10 years were 75 ± 4% and 62±4% for the entire group, respectively. Risk factors analysis revealed that time to disease recurrence had the strongest impact on outcome. Patients with progressive disease, representing 29% of all patients, accounted for 48% of later disease recurrences and 59% of deaths. In contrast, patients with late relapse, representing 38% of patients, contributed to 15% of later recurrences and death. OS and DFS in this group were 90±4% and 86±5%, respectively. Patients with early relapse, representing 32% of the entire cohort, experienced 38% of later recurrences and 27% of deaths. This translated into an OS of 78±11% and DFS of 55 ± 7%. Fifty-three patients in this study (30%) underwent autologous haematopoietic SCT (HSCT) following high-dose therapy, 18 of them in first relapse and 35 in second or subsequent relapses, but none of the patients with late relapses received HSCT.
Most reports on HSCT in HL involving paediatric and adolescent patients are included in studies on adult patients, some of which are discussed here as well, and only few analyses are limited to young patients. Here we provide an overview on paediatric and adolescent patients receiving autologous or allogeneic HSCT for recurrent HL.
Autologous HSCT
Conventional salvage therapy vs high-dose chemotherapy in adult patients and risk factors associated with outcome Autologous HSCT following high-dose therapy is the treatment of choice in adult patients with relapsing or progressive HL because several studies have suggested that high-dose chemotherapy followed by autologous HSCT gives superior results when compared with conventional salvage therapy for patients failing primary therapy. [10] [11] [12] [13] Josting et al.
14 for the German Hodgkin Study Group proposed a score for adult relapsed patients. The authors identified time to relapse, clinical stage and presence of anaemia at relapse as independent risk factors associated with an adverse outcome. Another study from the same group on 206 patients with primary progressive HL revealed that low performance status, failure of responding to first-line therapy and older age contributed to poor outcome. 15 Freedom from second failure and OS of 70 patients receiving high-dose therapy followed by autotransplantation were 31 and 43%, respectively, compared with 17 and 26% for all patients, respectively. In a French study of 157 patients with stage IIIB to IV, B symptoms at progression followed by salvage therapy without HSCT were adverse factors for OS and freedom from second failure in multivariate analysis. 13 Only two studies have been performed comparing conventional and high-dose therapy in a randomized manner, both showing better results for patients who received intensified treatment. Linch et al. 16 in the British National Lymphoma Investigation trial, compared 20 patients receiving BEAM followed by autologous BMT with 20 patients who received mini-BEAM without SCT. EFS and PFS were superior and relapse rate was lower for patients in the high-dose therapy group, whereas OS was similar in both groups. More recently, Schmitz et al. 17 in the German HD-R1 trial compared the outcome for patients with relapsed chemosensitive HL who received either BEAM followed by high-dose chemotherapy and autologous HSCT (n ¼ 61) or two cycles of Dexa-BEAM (n ¼ 56). Freedom from treatment failure at 3 years was significantly better for transplanted patients than for those receiving conventional salvage therapy (55 vs 34%, P ¼ 0.02). This difference was especially evident in patients with disease recurrence within 1 year after end of treatment (41 vs 12%, P ¼ 0.008). The difference was smaller but still significant for patients with late relapse (75 vs 44%, P ¼ 0.025). In contrast, patients with multiple relapses had a similar probability for freedom from treatment failure (34 vs 44%, P ¼ 0.37) with both approaches. OS was not significantly different, either for the whole cohort or for subgroups. These results were updated 3 years later. 18 At a median follow-up of 83 months, freedom from treatment failure for all patients was 49% in the transplant arm and it was 32% in the chemotherapy arm (P ¼ 0.02). The striking difference in favour of patients with early relapse receiving HSCT remained stable (42 vs 12%; Po0.01).
In an earlier study from the European Group for Blood and Marrow Transplantation (EBMT) on 175 adult patients without remission after induction therapy, the interval between diagnosis and HSCT had prognostic significance for OS in a multivariate analysis. 19 Majhail et al. 20 analysed 141 patients with primary refractory or relapsed HL. In multivariate analysis, chemoresponsiveness at the time of HSCT was predictive for OS and PFS and disease status at HSCT and presence of B symptoms at relapse before HSCT affected PFS. Regression analysis in a study from Stanford on 119 patients showed that the presence of B symptoms, disseminated pulmonary or BM involvement at relapse and disease status at HSCT were significant prognostic factors for EFS and OS. 21 Time to relapse and disease status at HSCT have emerged as the most important prognostic factors for outcome. Schmitz et al. 22 have shown that PFS in 11 patients with chemoresistant disease at HSCT was 0% as compared with 44% in 28 patients with chemosensitive disease (P ¼ 0.01). The OS of the total cohort was 61%. Patients with resistant disease show only moderate benefit, if any, after autologous HSCT. The outcome after disease progression following transplantation is poor. 23 Paediatric studies So far, limited data on the impact of autologous HSCT in paediatric HL have been published. Older series are rather small or have included children in adult series. 24, 25 Owing to the approximately 10 times higher occurrence of HL in adults compared with children and adolescents, the number of patients receiving HSCT in the younger age group are considerably smaller than those in adult patients. Inclusion criteria and age categories varied among different study groups displaying an upper age limit for paediatric patients between 15 and 21 years.
Williams et al., 26 in the largest published analysis on the impact of autologous HSCT in children so far, performed a case-control study of 81 paediatric patients younger than 16 years at diagnosis and 81 patients aged 16-50 years. All patients received autologous BM following high-dose therapy. Median age in the two age groups at HSCT was 16.9 years and 29.4 years, respectively. The outcome between the two groups was not statistically different. PFS rates were 39% as compared with 48% (P ¼ 0.64) and rates for disease recurrence were 52% and 40% (P ¼ 0.65). Further subgroup analysis of chemosensitive patients (n ¼ 42 in each group, P ¼ 0.72), chemoresistant patients (n ¼ 26 in each group, P ¼ 0.33) and patients receiving chemotherapy only for conditioning (n ¼ 76 per group, P ¼ 0.50) also revealed no difference in outcome between the two age groups. The authors also observed that females had a worse outcome, but this phenomenon awaits further investigation. Patients who were refractory to treatment had the poorest outcome regardless of age. The rate of procedure-related deaths and disease recurrence was similar in both groups.
Baker et al. 27 reported on 53 children and adolescents p21 years at the time of HSCT. Of those, 44 patients had received CY, etoposide and carmustine (CVB) for conditioning. Actuarial OS at 5 years was 43% and actuarial failure-free survival was 31%. The cause of death in 28 patients was progressive disease in 21 and transplantrelated complications in 7, respectively. Median time to relapse was 6 months. Risk factors with an impact on failure-free survival included high pre-transplant LDH levels (Pp0.001) and disease status at HSCT (P ¼ 0.06). The authors further subdivided age groups (o13, 13-18 and 19-21 years) but did not find any differences with regard to failure-free survival and OS. 27 In addition, when comparing this cohort with adult patients transplanted in the same institution, the authors obtained comparable results. Regardless of age, disease recurrence following autologous HSCT was the most important factor for failure and death.
Stoneham et al. 28 retrospectively analysed 51 children (age at diagnosis 3-16 years) who underwent autologous HSCT and compared the outcome with 78 patients who received conventional salvage therapy. BEAM was the conditioning regimen used for 44 patients (86%), and 76% of patients were in CR at the time of HSCT. The authors did not find a survival difference between patients given or not given high-dose therapy and HSCT. Restricting the analysis to 15 patients with progressive or resistant disease, however, showed that patients receiving high-dose chemotherapy and autologous HSCT had a survival advantage. In a comment on this article, 25 it was stressed that the two patient cohorts had different clinical characteristics and that more patients with adverse factors were belonging to the transplant cohort. The authors from Brazil also reported on their experience with nine patients; the OS at 36 months was 80% and DFS was 59%. 25 Frankovich et al.
29 studied 34 patients with a median age of 17 years at HSCT. In a multivariate analysis, the authors identified extranodal disease as a risk factor for DFS and OS and bulky disease at HSCT as a predictor for poor DFS. It can be noted that these authors observed 17 patients with pulmonary complications, 15 of them with idiopathic diffuse lung injury. Twelve of these patients had a history of atopy before HSCT. Using univariate analysis, atopy strongly predicted pulmonary complications (P ¼ 0.0001).
In a smaller Spanish study on 20 children with relapsed HL younger than 18 years at diagnosis, HSCT performed in first (n ¼ 1), second (n ¼ 12) or higher (n ¼ 3) CR resulted in a very favourable outcome. 30 After first-line treatment, 18 patients were in CR and two in PR. The projected OS and EFS rates were 95 and 62%, respectively. CVB was used in 11 (55%) patients.
A more recent report from Lieskovsky et al. 31 determined, in a multivariate analysis, primary induction failure, extranodal disease at relapse and mediastinal mass at HSCT as negative predictors for OS and EFS, the latter also contributing to a poor PFS. Of 16 patients who developed idiopathic diffuse lung injury syndrome, 11 had been treated with bleomycin. It can be noted that 15% of relapses occurred more than 2 years after HSCT. The authors therefore underscore the importance of long-term follow-up.
The German-Austrian experience 32 on 74 patients registered in the Paediatric Stem Cell Registry indicates that disease status at HSCT had the strongest impact on outcome. The probability for OS and PFS in that series was 59±6% and 50±6%, respectively. PFS for patients autografted in chemosensitive disease was 59 ± 6%, whereas it was 0% for those patients receiving an autotransplantation for chemorefractory disease (Figure 1 , Po0.0001).
Petropoulos et al. 33 described 13 children with 10 of them receiving post-transplant immunotherapy with low-dose IFN-a for up to 24 months. Nine of these patients were alive and in CR with a median follow-up of 67 months.
From the data available, no chemotherapy-based conditioning regimen has been shown to produce a superior outcome when compared with others. BEAM and CVB are the most widely used regimens. Because of the severe longterm effects, the use of TBI has become uncommon. Table 1 summarizes the key data of these studies, and two of them 32, 34 have been published as abstracts only.
Studies including paediatric patients in adult series
Several studies reporting on the outcome following autologous HSCT for progressive or relapsed HL have included a minority of children (o16 years) 20, 21, [35] [36] [37] [38] [39] [40] [41] [42] or adolescents (o18 years). 19, 23, 43 The median age of the patients at diagnosis in these studies was 27 years (range, 24-32 years) and 30 years (range, 24-36 years) at autologous HSCT.
In two large studies including 357 and 494 patients, respectively, Sureda et al. 41, 42 identified disease status at HSCT as an overwhelming prognostic factor in multivariate analysis for OS and time to treatment failure. Other significant variables for outcome were duration of first CR, year of HSCT, lines of pretreatment, presence of extranodal disease or B symptoms at HSCT, stage at HSCT and application of prior radiotherapy. Since the introduction of autologous HSCT for recurring HL, non-relapse mortality has continuously decreased to levels below 10%. 41 In a study including 187 patients with first relapse (median age at diagnosis: 30 years (range, 10-60 years), median age at relapse: 33 years), early disease recurrence and advanced stage at relapse were significant adverse factors, and high-dose therapy improved outcome. 44 None of these studies specifically addressed the impact of age as a possible prognostic factor. As discussed before, there is no evidence so far, that age at autologous HSCT is an independent factor associated with outcome in relapsed or refractory HL. 
Allogeneic HSCT
Allogeneic HSCT has become an effective tool in the treatment of malignant and non-malignant diseases in adults as well as in children. Alloreactive donor-derived T cells attacking the tumour cells of the recipient are largely responsible for the so-called GVL or graft-vs-lymphoma effect. Several lines of evidence also support the existence of a graft-vs-lymphoma effect in lymphoma. Patients receiving T-cell-depleted grafts or transplants from syngeneic twins have a higher risk for relapse. In addition, patients who develop chronic GVHD after HSCT have a reduced risk for developing disease relapse. Finally, the induction of CR by the infusion of donor lymphocytes, first demonstrated in chronic myeloid leukaemia but also in other diseases including lymphoma, is a strong indicator for the presence of a graft-vs-lymphoma effect. 45, 46 Toxicity of conditioning regimens, post-transplant immunosuppression and occurrence of GVHD, in particular, contribute to morbidity and mortality of this procedure. In addition, the limited availability of HLA compatible-related donors in a society with small families has initially hampered a broader use of this approach. To offer allogeneic transplantation to more patients who would not otherwise have been eligible for allogeneic HSCT, efforts have been undertaken to reduce procedure-related deaths by introducing conditioning regimens with reduced intensity.
Studies on allogeneic HSCT for relapsed and progressive HL
Owing to a very high rate of non-relapse mortality (NRM) of up to 60%, thus outweighing the potentially beneficial effect of lower relapse rates, initial studies were unable to demonstrate an advantage of allogeneic HSCT. [47] [48] [49] [50] The main factors causing these disappointing results were GVHD and infectious complications in heavily pretreated patients. Therefore, the role of allogeneic HSCT in patients with HL is being discussed controversially up to now.
Jones et al. 51 were among the first authors providing evidence for a graft-vs-lymphoma effect by allogeneic HSCT in 118 lymphoma patients, the majority having non-Hodgkin's lymphoma. They compared autologous with allogeneic HSCT in a retrospective analysis. EFS was not different between patients receiving an autologous and allogeneic HSCT, but relapse rate was significantly lower in patients who were allografted (18 vs 46%, P ¼ 0.02). 51 Patients with resistant lymphoma had a dismal prognosis. Long-term analysis of 157 lymphoma patients with relapsed or refractory HL, 104 receiving autologous HSCT and 53 receiving BM from HLA-matched siblings, revealed high relapse rates and no significant differences in EFS and OS in both arms. 52 There was a trend for a lower risk of relapse in patients with chemosensitive disease who received allogeneic HSCT, especially in those who developed GVHD. More recent studies using myeloablative conditioning regimens have reported lower NRM rates of 22%. Besides disease status at HSCT and type of donor, disease type and the use of TBI were significant prognostic factors for PFS and death. 53 On behalf of the Lymphoma Working Party of the EBMT, Robinson et al. 54 analysed 188 patients with resistant or aggressive lymphoma after reduced-intensity conditioning. They included 52 patients with HL. Twothirds had been autografted but subsequently relapsed, and up to six prior lines of therapy had been given before allogeneic HSCT. In multivariate analysis, disease status had a significant impact on OS as well as PFS, whereas older patients had a higher NRM rate. OS and PFS at 2 years were 56 and 42%, respectively.
Other groups have confirmed low NRM rates following reduced-intensity conditioning. In the study by Anderlini et al., 55 early NRM was 5% at day þ 100. The authors used fludarabine with melphalan (n ¼ 26) or CY (n ¼ 14) for conditioning. OS was better with the use of melphalan (P ¼ 0.02) thus it was concluded that a more intensive regimen is necessary for disease control.
In a multicentre study, Peggs et al. 56 from United Kingdom transplanted 49 patients with multiple relapses following conditioning with fludarabine and melphalan. Alemtuzumab was given for GVHD prophylaxis. All patients engrafted, 16% developed acute GVHD grade II-IV and 14% developed chronic GVHD. NRM of patients with HLA compatible-related donors was very low at 2 years (7%). The projected OS and PFS at 4 years were 56 and 39%. Sixteen patients received additional donor lymphocytes for disease persistence or recurrence, and nine of them achieved a PR or CR. In a collaboration between the groups from Spain and United Kingdom using fludarabine and melphalan for conditioning, different GVHD prophylaxis regimens were studied. Thirty-one patients had received CYA/alemtuzumab and the remaining 36 patients had received CYA/MTX. The use of alemtuzumab resulted in a lower rate of NRM, and acute and chronic GVHD without producing significantly more relapses. 57 PFS in the group treated with alemtuzumab was 43%, compared with 25% in patients receiving MTX for GVHD prophylaxis (P ¼ 0.036). OS was best in patients transplanted in CR. Thus, GVHD could be reduced by maintaining disease control. Moreover, durable responses to donor lymphocytes could be achieved.
The largest and most recent EBMT analysis on 168 patients comparing conventional with reduced-intensity conditioning regimens by Sureda 58 showed a significantly reduced NRM rate in the latter group (23 vs 46%, Po0.001) without an increase in relapse (Figure 2 ). The development of chronic GVHD resulted in a lower relapse rate (P ¼ 0.05), thus supporting the concept of a graft-vslymphoma effect. Adverse factors for OS in multivariate analysis were chemoresistant disease, myeloablative conditioning and an earlier failed autologous HSCT. Despite these achievements, relapse remains the most important cause of treatment failure in both groups. Table 2 summarizes the key findings of studies including children and adolescents on allogeneic HSCT for relapsed or progressive HL.
Paediatric studies
In contrast to the situation in adult patients 52, 54, 56, [59] [60] [61] [62] only small series or case reports are available on allogeneic HSCT in paediatric patients and adolescents. 63 From 1990 to 2007, 1395 HSCT for HL in patients o18 years at transplantation have been reported to the EBMT, compared with 17 556 transplants for adults in the same time period (EBMT Lymphoma Working Party, with permission). As in adults, the proportion of allogeneic HSCT in children for HL is below 10% of the total number of transplants, although the number has increased in recent years (Figure 3a) . Since the introduction of reducedintensity conditioning regimens to reduce the high NRM rate, the proportion of myeloablative regimens has decreased (Figure 3b) .
In a small paediatric study on six heavily pretreated patients from the GPOH HD-95 trial, conditioning included fludarabine with BU with or without CY or melphalan. 63 Patients had been pretreated with up to five lines of treatment including autologous HSCT in two. At the time of allogeneic HSCT, two patients had sensitive disease and four were refractory. Two patients died of infections before days þ 100 and one died 7 months after HSCT because of relapse. Two patients relapsed but responded to withdrawal of immunosuppresion, chemotherapy and application of donor lymphocytes. Both patients developed chronic GVHD necessitating systemic treatment.
Bradley and Cairo 64 published in abstract form a list of 10 patients who underwent autologous HSCT followed by tandem allogeneic transplantation. Conditioning regimens consisted of CVB and fludarabine/BU, respectively.
None of the published studies has specifically compared the influence of age between paediatric and adult patients on the outcome so far. Some studies have included few children [47] [48] [49] 51, 52, 54, 60 but age at HSCT was not reported to exert an effect on outcome. Older patients in the study by 
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A retrospective analysis of the Lymphoma and Paediatric Diseases Working Parties of the EBMT focusing on 151 patients o18 years at diagnosis who received allogeneic HSCT following salvage therapy showed an OS of 54% at 2 years. 65 Earlier autologous HSCT had failed in 55% of the patients. PFS at 2 years was 39% and NRM rate at 1 year was 20%. The main adverse factor for increased NRM in multivariate analysis was HLA disparity between donor and recipient, whereas low performance contributed to an inferior OS. Performance and disease status at HSCT had a significant impact on PFS and relapse rate. In that study, there was no obvious difference in outcome between patients transplanted o18 years or between 18 and 21 years. 65 
Conclusions
The type of salvage therapy for paediatric and adolescent patients with HL failing first-line therapy should be chosen according to the characteristics of disease failure and treatment response. Although patients with limited disease and late relapses have a very good outcome with standardized salvage therapy, thus avoiding potential sequelae of high-dose therapy, treatment intensification will be necessary for patients with early disease recurrence or progression. 66 The majority of these patients will undergo autologous HSCT, and radiotherapy should be considered to eradicate residual lymphoma. The most important predictors for disease control following autologous HSCT are time to relapse and disease status at transplantation. The introduction of positron emission tomography in the evaluation of treatment response will provide important data on the importance of disease status before the transplantation. Despite limited experience in children, allogeneic HSCT should be considered for selected paediatric and adolescent patients. Candidates for allogeneic HSCT are patients with disease recurrence after autologous HSCT and possibly those experiencing multiple relapses. The impact of allogeneic HSCT in patients with chemoresistant lymphoma remains unclear, although there have been reports of patients with durable responses. As relapse has evolved as the main problem following allogeneic HSCT, the optimal conditioning regimen, the time point of transplantation, GVHD prophylaxis and post-transplant approaches, such as immunotherapy or targeted therapy, have to be defined. Importantly, most paediatric patients with HL develop their disease as older children or young adolescents, and those with disease recurrence will be transplanted as older adolescents or young adults. Prospective trials will be mandatory to answer these questions. In addition, as cutoff points for adulthood vary from country to country and there are no striking data from published data that recurring HL biologically differs in adolescents and young adults, cooperative studies including both groups especially in the allogeneic setting might be valuable. 
